Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBP501 with Pemetrexed and Cisplatin in Advanced Non-Squamous NSCLC
NCT00942825Phase 2Completed
- Sponsor
- CanBas
- Start
- Apr 2009
- Primary completion
- Jul 2013
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of CBP-501 in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC) (2 arms), sponsored by CanBas. Primary endpoint: Progression Free Survival. Started Apr 2009; status: completed.
02
Drugs
CBP-501
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT00942825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00942825.